Publications and Presentations

  1. Single-Site Labeling of Native Proteins Enabled by a Chemoselective and Site-Selective Chemical Technology. Oct 17, 2018. Adusumalli SR, Rawale DG, Singh U, Tripathi P, Paul R, Kalra N, Mishra RK, Shukla S, Rai V. J. Am. Chem. Soc., 2018, 140 (44), pp 15114–15123. DOI: 10.1021/jacs.8b10490

  2. Gupta A, Athira A, Panday RK, Samaiya A, Shukla S*. PAK2-c-MYC-PKM2 axis plays an essential role in head and neck oncogenesis via regulating Warburg effect. Cell Death & Disease 9: 825 (2018)

  3. Chilamari M, Kalra N, Shukla S, Rai V. Single-site labeling of lysine in proteins through a metal-free multicomponent approach. Chem. Commun., 2018,54, 7302-7305 (2018).

  4. Singh S, Narayanan SP, Biswas S, Gupta A, Ahuja A, Yadav S, Panday RK, Samaiya A, Sharan SK, Shukla S*. Intragenic DNA methylation and BORIS mediated cancer-specific splicing contributes to Warburg effect. Proc Natl Acad Sci U S A (2017) 114 (43): 11440-45  doi: 10.1073/pnas.1708447114
  5. Narayanan SP, Singh S, Shukla S*. A saga of cancer epigenetics: linking epigenetics to alternative splicing. Biochemical J. (2017) 474(6): 885-896.
  6. Marina RJ, Sturgill D, Bailly MA, Thenoz M, Varma G, Prigge MF, Nanan KK, Shukla S, Haque N, Oberdoerffer S.TET-catalyzed oxidation of intragenic 5-methylcytosine regulates CTCF-dependent alternative splicing. EMBO J. (2016) 35(3):335-55
  7. Narayanan SP, Singh S, Gupta A, Yadav S, Singh SR, Shukla S*. Integrated genomic analyses identify KDM1A's role in cell proliferation via modulating E2F signaling activity and associate with poor clinical outcome in oral cancer. Cancer Letters (2015) 367: 162–172.
  8. Pranay A, Shukla S, Kannan S, Malgundkar SA, Govekar RB, Patil A, Kane SV, Chaturvedi P, D'Cruz AK, Zingde SM. Prognostic utility of autoantibodies to α-enolase and Hsp70 for cancer of the gingivobuccal complex using immunoproteomics. Proteomics Clinical Applications (2013) 7(5-6): 392-402.
  9. Shukla S., Oberdoerffer S. Co-transcriptional regulation of alternative pre-mRNA splicing. BBA-Gene Regulatory Mechanism (2012) 1819 (7): 673-683.
  10. Shukla S, Kavak E, Gregory M, Imashimizu M, Shutinoski B, Kashlev M, Oberdoerffer P, Sandberg R,    Oberdoerffer S. “CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing”.    Nature (2011) 479: 74–79 (Research highlight: This article was highlighted at; 

    Cell Research- Kornblihtt A“CTCF: from insulators to alternative splicing regulation”, Cell Research 2012 Mar; 22(3): 450–452.

    CCR Connections Vol 6 (1), 2012 “CTCF, a Novel Regulator of Alternative Splicing” https://home.ccr.cancer.gov/connections/dev/2012/Vol6_No1/news_7.asp

    Received F1000 article factor (FFa) -17 (exceptional rating) from Faculty of 1000. https://f1000.com/13371987)

     
  11. Shukla S, Pranay A, D’Cruz AK, Chaturvedi P, Kane SV, Zingde SM “Immunoproteomics reveals that cancer of the tongue and the gingivo buccal complex exhibit differential autoantibody response.” Cancer Biomarkers (2009) 5(3): 127-35.
  12. Shukla S, Govekar RB, Sirdeshmukh R, Sundaram CS, D’Cruz A, Pathak KA, Kane SV, Zingde SM Tumor antigens eliciting autoantibody response in cancer of gingivo-buccal complex. Proteomics Clinical Applications (2007) 1(12): 1592-1604.

Patent:

  1. Zingde, Shukla, Sirdeshmukh, Sundaram D’Cruz, Pathak, Kane [Inventors] Autoantibodies for protein antigens as markers for cancer of the ginigivo–buccal complex:

US Patent granted: US 8492100 B2

European Patent granted: EP2126578 (Published: Feb 12, 2009)

CSIR: Ref No: 0187NF 2006/1N, filed on Feb 14, 2007; 290DEL 2007